Literature DB >> 19836257

Does induction treatment increase the risk of morbidity and mortality after pneumonectomy? A multicentre case-matched analysis.

Majed Refai1, Alessandro Brunelli, Gaetano Rocco, Mark K Ferguson, Sergio N Fortiparri, Michele Salati, Antonello La Rocca, Kenji Kawamukai.   

Abstract

BACKGROUND: The objective of this investigation was to compare postoperative morbidity and early and late mortality in patients after pneumonectomy for non-small-cell lung cancer (NSCLC) with or without induction neo-adjuvant therapy.
METHODS: This is an observational study performed on prospectively collected data at four tertiary referral centres (2000-2007). Of 225 pneumonectomies for NSCLC, 81 patients underwent neo-adjuvant chemotherapy. Several perioperative variables were used in identifying propensity score-matched pairs of patients with and without induction treatment. The matched groups were then compared in terms of morbidity, early (30-day or in-hospital) and 90-day mortality.
RESULTS: The overall cardiopulmonary morbidity, early mortality and 90-day mortality rates were 30% (67 patients), 7.1% (16 patients) and 9.8% (22 patients), respectively. Propensity score analysis yielded 56 well-matched pairs of patients with and without induction chemotherapy. The two groups had similar early and late mortality rates: four versus four (p=1) and seven versus seven (p=1), respectively. Moreover, the incidence of cardiopulmonary morbidity and bronchopleural fistula were also similar in both the groups: 19 versus 17 patients (Fisher's exact test p=0.7) and two versus three patients (Fisher's exact test, p=0.7), respectively. Twenty-one patients with induction chemo-radiotherapy were analysed separately and compared with well-matched counterparts without any induction treatment. No significant differences were identified in terms of early mortality (1 vs 0, p=1), 90-day mortality (1 vs 0, p=1), cardiopulmonary complications (5 vs 5, p=1) and bronchopleural fistula (1 vs 1, p=1).
CONCLUSIONS: Current regimens of induction treatment do not seem to increase the risk of morbidity, early mortality and late mortality after pneumonectomy in properly selected patients. This study warrants confirmation from future multicentre prospective randomised trials powered on early outcomes. Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19836257     DOI: 10.1016/j.ejcts.2009.09.018

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Comprehensive treatment approach is necessary for the closure of open window thoracostomy: an institutional review of 35 cases.

Authors:  Tai Hato; Shigeki Suzuki; Masahiko Harada; Hirotoshi Horio
Journal:  Surg Today       Date:  2013-03-24       Impact factor: 2.549

2.  Use of staplers and adverse events in thoracic surgery.

Authors:  Dragan Subotic; Aljaz Hojski; Mark Wiese; Didier Lardinois
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

Review 3.  Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.

Authors:  Ya-Ping Xu; Bo Li; Xiao-Ling Xu; Wei-Min Mao
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

4.  Major pulmonary resection after neoadjuvant chemotherapy or chemoradiation in potentially resectable stage III non-small cell lung carcinoma.

Authors:  Michael Peer; Sharbel Azzam; Arnold Cyjon; Rivka Katsnelson; Henri Hayat; Ilan Bar; Ofer Merimsky
Journal:  Sci Rep       Date:  2021-10-12       Impact factor: 4.379

5.  Neoadjuvant chemotherapy is a risk factor for bronchopleural fistula after pneumonectomy for non-small cell lung cancer.

Authors:  Ozgur Samancilar; Seyda Ors Kaya; Ozan Usluer; Taner Ozturk
Journal:  Kardiochir Torakochirurgia Pol       Date:  2014-03-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.